Background. A 9-valent human papillomavirus-6/11/16/18/31/33/45/52/58 (9vHPV) vaccine extends coverage to 5 next most common oncogenic types (31/33/45/52/58) in cervical cancer versus quadrivalent HPV (qHPV) vaccine. We describe efficacy, immunogenicity, and safety in Asian participants (India, Hong...
Bibliographische Detailangaben
| Veröffentlicht in: | The Journal of Infectious Diseases. - Oxford University Press. - 218(2018), 1, Seite 95-108
|
|---|
| 1. Verfasser: |
Garland, S. M.
(VerfasserIn) |
|---|
| Weitere Verfasser: |
Pitisuttithum, P.,
Ngan, H. Y. S.,
Cho, C.-H.,
Lee, C.-Y.,
Chen, C.-A.,
Yang, Y. C.,
Chu, T.-Y.,
Twu, N.-F.,
Samakoses, R.,
Takeuchi, Y.,
Cheung, T. H.,
Kim, S. C.,
Huang, L.-M.,
Kim, B.-G.,
Kim, Y.-T.,
Kim, K.-H.,
Song, Y.-S.,
Lalwani, S.,
Kang, J.-H.,
Sakamoto, M.,
Ryu, H.-S.,
Bhatla, N.,
Yoshikawa, H.,
Ellison, M. C.,
Han, S. R.,
Moeller, E.,
Murata, S.,
Ritter, M.,
Sawata, M.,
Shields, C.,
Walia, A.,
Perez, G.,
Luxembourg, A. |
|---|
| Format: | Online-Aufsatz
|
|---|
| Sprache: | English |
|---|
| Veröffentlicht: |
2018
|
|---|
| Zugriff auf das übergeordnete Werk: | The Journal of Infectious Diseases
|
|---|
| Schlagworte: | 9vHPV
Asia
cervical cancer
human papillomavirus
vaccine |
|---|